Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse (Q46754499)

24 December 2017

title

Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse (English)

1 reference

24 December 2017

main subject

ezetimibe

1 reference

metabolic dysfunction–associated steatotic liver disease

ChEBI release 2020-05-28

ChEBI ID

49040

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

10

1 reference

24 December 2017

author name string

Xiang Wang

1

1 reference

24 December 2017

Ken Sugimoto

2

1 reference

24 December 2017

Tomomi Fujisawa

3

1 reference

24 December 2017

Nobuyasu Shindo

4

1 reference

24 December 2017

Satomi Minato

5

1 reference

24 December 2017

Yoshihiro Kamada

6

1 reference

24 December 2017

Mina Hamano

7

1 reference

24 December 2017

Mitsuru Ohishi

8

1 reference

24 December 2017

Hiroshi Ikegami

9

1 reference

24 December 2017

publication date

19 March 2013

1 reference

24 December 2017

published in

Hepatology Research

1 reference

24 December 2017

volume

44

1 reference

24 December 2017

issue

1

1 reference

24 December 2017

page(s)

102-113

1 reference

24 December 2017

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

A novel mouse model for type 2 diabetes and non-alcoholic fatty liver disease: spontaneous amelioration of diabetes by augmented beta cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

The SCF ubiquitin ligase: insights into a molecular machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Ubiquitin ligases: cell-cycle control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Melatonin prevents disruption of hepatic reactive oxygen species metabolism in rats treated with carbon tetrachloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

Romo1 is a negative-feedback regulator of Myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12092

21 January 2018

Identifiers

DOI

10.1111/HEPR.12092

1 reference

24 December 2017

PubMed ID

23510093

1 reference

24 December 2017